Kymera Therapeutics, Inc. KYMR 深 沪
等待开盘 02-11 09:30:00 美东时间
79.49
+0.470
+0.59%
华盛通- 最 高80.95
- 今 开78.75
- 成交量 120.72万股
- 最 低 78.135
- 昨 收 79.02
- 总市值 62.76亿
- 52周最高 103.00
- 市盈率 静 --
- 换手率 1.53%
- 52周最低 19.445
- 委 比 -49.81%
- 总股本 7894.90万
- 历史最高 103.00
- 量 比 1.48
- 振 幅 3.56%
- 历史最低 9.60
- 每 手 1
- 风险率 17.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kymera Starts Mid-Stage Trial of New Oral Asthma Drug, Data Expected in 2027
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated
01-29 20:09
Kymera Therapeutics Doses First Patient in Phase 2b Asthma Trial of KT-621
Kymera Therapeutics Doses First Patient in Phase 2b Asthma Trial of KT-621 Kymera Therapeutics Inc. has announced the initiation of dosing in its BREADTH Phase 2b clinical trial evaluating KT-621, a first-in-class oral STAT6 degrader, in patients with moderate to severe eosinophilic asthma. The comp
01-29 20:00
美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $133
Barclays analyst Etzer Darout maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $119 to $133.
01-28 23:02
美股大行评级 | 阿斯麦、美光科技、SanDisk获大行上调目标价；美国银行、富国银行绩后遭多家机构下调目标价
今日重点评级关注：Benchmark：维持TNL Mediagene"投机性买入"评级，目标价从3.5美元升至14美元；康托·菲茨杰拉德：维持Eupraxia Pharmaceuticals"超配"评级，目标价从11美元升至19美元
01-16 10:04
Kymera Therapeutics Sets 2026 Clinical Strategy and Milestones
The latest announcement is out from Kymera Therapeutics ( ($KYMR) ). On January...
01-13 20:29
Kymera Therapeutics Highlights 2026 Pipeline Milestones; KT‑621 Phase 2b In AD Ongoing, Asthma Trial Initiated, KT‑579 Phase 1 Starting 1Q26, New Oral Immunology IND Candidate Advancing, $1.6B Cash Runway Into 2029
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027KT-579 Phase 1 HV clinical trial expected to start in 1Q26,
01-13 20:03
Wolfe Research Downgrades Kymera Therapeutics to Peer Perform
Wolfe Research analyst Andy Chen downgrades Kymera Therapeutics (NASDAQ:KYMR) from Outperform to Peer Perform.
01-06 21:19
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
Kymera Therapeutics announced it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026. Nello Mainolfi, CEO, will discuss the company's progress and 2026 milestones. A live webcast and replay will be available on the company's website. Kymera specializes in targeted protein degradation to treat immunological diseases, aiming to develop innovative therapies. For more information, visit www.kymeratx....
01-06 12:00
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
